CARBIDOPA; LEVODOPA | A074260 | ACTAVIS ELIZABETH LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara, P. C. FDA-2020-P-0129 · 5 docket documents On January 8, 2020, the law firm Hyman, Phelps & McNamara filed a citizen petition with the FDA requesting that the agency designate ANDA 074260 held by Actavis Elizabeth LLC or another appropriate ANDA as a new reference standard for Carbidopa and Levodopa Tablets in strengths of 25 mg/250 mg, 25 m | 505(q) | 2020-01-08 | Withdrawn | Hyman, Phelps & McNamara, P. C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1112
per ea
Lowest NADAC/Unit
$0.0732
per ea
Brand NDCs
0
Generic NDCs
10
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093970301CARBIDOPA-LEVODOPA 25-250 TAB | $0.1112 | EA | Generic | — | 2026-06-17 |
| 00093970305CARBIDOPA-LEVODOPA 25-250 TAB | $0.1112 | EA | Generic | — | 2026-06-17 |
| 00093970310CARBIDOPA-LEVODOPA 25-250 TAB | $0.1112 | EA | Generic | — | 2026-06-17 |
| 60687083601CARBIDOPA-LEVODOPA 25-250 TAB | $0.1112 | EA | Generic | — | 2026-06-17 |
| 00093970105CARBIDOPA-LEVODOPA 10-100 TAB | $0.0760 | EA | Generic | — | 2026-06-17 |
| 00093970101CARBIDOPA-LEVODOPA 10-100 TAB | $0.0760 | EA | Generic | — | 2026-06-17 |
Showing 6 of 10 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.